Revance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note issued on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

A number of other research firms also recently issued reports on RVNC. Piper Sandler downgraded shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 12th. Barclays reissued an “equal weight” rating and issued a $7.00 price objective (down previously from $10.00) on shares of Revance Therapeutics in a research report on Friday, September 13th. William Blair restated a “market perform” rating on shares of Revance Therapeutics in a report on Monday, August 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Finally, Stifel Nicolaus cut their price objective on Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $9.66.

Revance Therapeutics Stock Down 5.8 %

Shares of RVNC opened at $3.76 on Monday. The firm has a market cap of $394.42 million, a PE ratio of -2.05 and a beta of 0.95. The company’s fifty day moving average is $5.36 and its two-hundred day moving average is $4.45. Revance Therapeutics has a fifty-two week low of $2.30 and a fifty-two week high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The company had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $67.73 million. As a group, equities research analysts anticipate that Revance Therapeutics will post -1.54 earnings per share for the current year.

Institutional Investors Weigh In On Revance Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RVNC. Certuity LLC acquired a new stake in shares of Revance Therapeutics during the second quarter valued at about $26,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Revance Therapeutics during the 2nd quarter valued at approximately $33,000. Hsbc Holdings PLC purchased a new stake in Revance Therapeutics during the 2nd quarter worth approximately $38,000. Nisa Investment Advisors LLC raised its position in shares of Revance Therapeutics by 2,167.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 18,077 shares in the last quarter. Finally, FORA Capital LLC acquired a new position in shares of Revance Therapeutics in the 3rd quarter valued at approximately $54,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.